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The development of intimal hyperplasia (IH)
poses a significant clinical problem in both the coro-
nary and the peripheral circulations. Thus, up to
40% of the coronary and the peripheral arteries
develop restenosis after angioplasty as a result of IH,
and up to 35% of saphenous vein bypass grafts devel-
op patency-threatening stenoses within the 1st post-
operative year, which again results from localized
areas of IH.1-4 In addition to its vasoconstrictor
actions,5 endothelin-1 (ET-1) is also a powerful
mitogen for vascular smooth muscle cells.6-8
Considerable interest therefore has been directed
towards its potential role as a mediator of IH. A role
for ET-1 in the development of IH in human vessels
is suggested by the finding that ET-1 is mitogenic
for human saphenous vein smooth muscle cells9 and
that ET-1 expression is increased in human saphe-
nous vein graft stenoses.10 In addition, it has recent-
ly been shown11 that ET-1 immunoreactivity is
greatly increased in transplant coronary artery dis-
ease, a condition characterized by IH. Because most
of the ET-1 produced by endothelial cells is released
abluminally,12 increased plasma ET-1 levels would
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Objective: Although a number of pharmacologic agents have been shown to reduce inti-
mal hyperplasia in animal models of restenosis, to date no systemic agent has conclu-
sively been shown to be effective in humans. Recently, considerable attention has been
directed towards endothelin (ET), a potent vasoconstrictor and a powerful mitogen for
vascular smooth muscle cells, as a mediator of intimal hyperplasia. Endothelin-1 has
been shown to be mitogenic for human saphenous vein smooth muscle cells, and expres-
sion also is elevated in human vein graft stenosis. The aim of this study was the investi-
gation of whether ET receptor antagonists can attenuate neointima formation in a lab-
oratory model of vein graft intimal hyperplasia and the determination of whether the
effects are mediated by a specific ET receptor subtype.
Methods: We used an organ culture of human saphenous vein, a well-validated model of
vein graft intimal hyperplasia. Paired segments of human long saphenous vein were cul-
tured with and without the following antagonists: bosentan, a nonselective ET receptor
antagonist; BQ 123, a specific endothelin-A antagonist; or BQ 788, a specific endothe-
lin-B (ETB) antagonist. After 14 days in the culture, the segments were fixed and
processed and the sections were immunostained to facilitate the measurements of neoin-
timal thickness with a computerized image analysis system.
Results: The nonselective antagonist bosentan and the ETB selective antagonist BQ 788
significantly reduced neointima formation by 70% (P = .001) and 50% (P = .03), respec-
tively, but the ETA antagonist BQ 123 had no significant effect on the reduction of
neointima formation (P = 1.0).
Conclusion: The results of this study imply an important role for ET as a mediator of
human vein graft intimal hyperplasia and imply further that a specific ETB antagonist
may have a therapeutic potential for the prevention of vein graft stenosis. (J Vasc Surg
1998;28:695-701.)
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suggest a markedly increased production of the pep-
tide at localized sites. 
Two main receptor subtypes for ET-1 have been
identified and are designated endothelin-A (ETA)
and endothelin-B (ETB).13,14 Both receptor sub-
types have been shown to coexist in vascular smooth
muscle cells from normal human internal mammary
arteries and veins15 and from human coronary arter-
ies and saphenous veins.16 In the normal human
coronary artery and saphenous vein, approximately
10% of the receptors in the media are ETB and 90%
are ETA, whereas in atherosclerotic vessels, the pro-
portion of ETB receptors rises to 50%.17
In vitro studies in early passaged cultured rat aor-
tic smooth muscle cells have shown that ET-1
induced smooth muscle cell mitogenesis and prolif-
eration are mediated through the ETA, but not the
ETB, receptor subtype18 and that the mitogenic
activity of ET-1 correlates with ETA receptor bind-
ing and density.19 However, this mitogenic response
seems to be subject to phenotypic modulation
because it has also been shown that repeated passag-
ing of smooth muscle cells leads to increased ETB
expression to the extent that selective ETA antago-
nism no longer inhibits the mitogenic activity of ET-
1.20 Eguchi et al21 have shown that the phenotypic
change of vascular smooth muscle cells in culture is
concommitantly associated with a change in the
endothelin (ET) receptor subtype that potentiates
mitogenic activity. This suggests that the switching
of the ET receptor subtype from A to B during phe-
notypic change may, in part, contribute to the devel-
opment of vascular lesions. In support of this
hypothesis, Azuma et al22 showed an increased den-
sity of ETB receptors in the neointima of hyperplas-
tic rabbit arteries. The administration of a specific
ETA antagonist BQ 123 failed to have any effect on
the reduction of neointimal thickness, even at con-
centrations that were sufficient to fully antagonize
the ETA receptors.
In recent years, there has been a growing inter-
est in the role of ET in a wide variety of disease states
and a number of ET receptor antagonists have been
developed. If ET-1 plays a central role in the cause
of IH, then ET receptor antagonists may have ther-
apeutic potential. Indeed, Douglas et al23 have
shown that ET-1 can promote neointima formation,
and they have further demonstrated that, in the rat,
a potent ET receptor antagonist, SB 209670,
reduces IH in injured carotid arteries.18 One impor-
tant question is whether the pathophysiologic mech-
anisms of restenosis shown in animal models also
apply to the clinical situation. A number of studies
show the therapeutic benefit of ET receptor antago-
nism by reduction of neointima formation in animal
models of restenosis,24-26 but many other pharma-
cologic agents that have been shown to be effective
in small animals have not been reproducible in
human studies, which thereby highlights the limita-
tions of animal models.27 In human saphenous vein
used as an arterial bypass graft conduit, the roles of
ET-1 and of the receptors involved with respect to
the development of IH have not been studied. The
purpose of this study was the investigatation of
whether ET receptor antagonists can ameliorate IH
in cultured human saphenous vein and, hence, the
determination of whether this is effected via the ETA
receptor, ETB receptor, or both. We investigated the
following 3 compounds: bosentan, the most potent
orally active mixed antagonist of ET receptors so far
described;28 BQ 123, a selective antagonist of the
ETA receptor;29 and BQ 788, a selective antagonist
of the ETB receptor.30 We used an organ culture of
human long saphenous vein (LSV), a well-validated
model of IH31 in which, after a 14-day culture peri-
od, vessels develop a cellular neointima that has
many of the characteristics of IH seen in vivo.31
PATIENTS AND METHODS
Culture method. For each ET receptor antag-
onist, segments of the LSV were obtained from a
minimum of 10 patients who underwent arterial
bypass grafting. The segments were transported to
the laboratory in a calcium-free physiologic saline
solution and prepared for culture with a method
previously described.31 Local ethical committee
approval was obtained. Briefly, the excess fat and the
adventitial tissue were dissected from the vessels,
which were then opened longitudinally and cut into
0.5-cm lengths. The vessels were pinned, lumenal
surface uppermost, with fine minuten pins (Watkins
and Doncaster, Cranbrook, United Kingdom) onto
a 500-m m mesh that rested on a layer of preformed
Sylgard resin (Dow Corning, Seneffe, Belgium) in
the the bottom of a 60 · 20–mm glass petri dish.
This method of vein culture has been reported pre-
viously31-34 and has been validated extensively in our
laboratory as a representative in vitro model of the
changes that occur in vein-graft IH in vivo.31 The
pinning of flat vein segments was the chosen method
because of limitations on the amount of tissue that
could reasonably be spared at the time of surgery. To
eliminate the possibility of artifactual measurements
of the vein wall, we performed an initial validation
study to compare the pinning method of flat seg-
ments of vein with perfusion through the intact vein.
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The mean difference of intimal thickness between
the 2 methods then was evaluated. From this evalu-
ation, we concluded that there was a highly signifi-
cant level of agreement between the 2 methods of
fixation.35 Cultures were maintained in RPMI 1640
medium (Northumbria Biologicals, Cramlington,
United Kingdom) and supplemented with 30% fetal
calf serum (Seralab, Crawley Down, United
Kingdom) for 14 days at 37°C in a humidified
atmosphere of 5% CO2 in the air. Consecutive seg-
ments were prepared from each vessel, such that
they were equivalent before randomization to the
different treatment groups. In each group, 1 seg-
ment served as control, and to the others, either
bosentan (10 m mol/L), BQ 123 (1 m mol/L and 3
m mol/L), or BQ 788 (1 m mol/L and 3 m mol/L)
were added. Bosentan generously was provided by
Roche Products Ltd (Welwyn Garden City, United
Kingdom), and BQ 788 and BQ 123 were pur-
chased from Calbiochem-Novabiochem Ltd
(Nottingham, United Kingdom). All compounds
were prepared in a 10% dimethyl sulfoxide solution,
and the control veins received an equivalent volume
of vehicle only. The culture medium and the drugs
were replaced every 2 to 3 days, and, after 14 days,
while still pinned in the culture dishes, the segments
were fixed overnight in 10% formalin solution,
processed, and embedded in paraffin. Transverse
sections of 4-m m thickness were double-stained with
a combined monoclonal anti–smooth muscle actin
and Miller’s elastin stain36 to identify the layers of
the vein wall. Mouse anti–human alpha smooth
muscle actin antibody (Dako, High Wycombe,
United Kingdom) was applied at a ratio of 1:400,
and diaminobenzidine was used as a final reaction
product. After this procedure, a Miller’s elastin stain
was superimposed.37
Measurement of neointimal thickness. The
measurements of neointimal thickness were made on
transverse sections of each vessel with a computer-
ized image analysis system (Improvision, Coventry,
United Kingdom). Thirty measurements were made
on each vein evenly distributed across the whole sec-
tion. The measurements were performed by 2 inde-
pendent observers, with a high level of agreement
(interobserver error). The measurements for any 1
section were found to be both consistent and repro-
ducible (intraobserver error).35
Statistics. All of the summary data are expressed
as median and range. The differences between the
neointimal thickness of the paired control and the
drug-treated veins were analyzed with a Wilcoxon
signed rank test, with 95% confidence intervals.
RESULTS
Neointimal thickness. The histologic examina-
tion of the immunostained segments revealed that
the control veins all developed a significant neointi-
ma composed of several layers of smooth muscle
actin–positive cells after 14 days in culture (Fig 1,
A). The vein segments that were treated with the
mixed antagonist bosentan developed significantly
less neointima than the paired control veins (Fig 1,
B). The median neointimal thickness of the control
veins was 16.75 m m (range, 5 to 34 m m) versus the
bosentan-treated veins at 4.5 m m (range, 0 to 17
m m). The median difference was 11.5 m m, with 95%
confidence intervals that were 8.75 and 15.0 (P =
.001; Fig 2).
Similarly, the veins that were treated with the spe-
cific ETB antagonist BQ 788 also showed significantly
less neointimal thickening than did the control veins at
both the 1- m mol/L and the 3- m mol/L concentra-
tions. The median neointimal thickness of the control
veins in this group was 28 m m (range, 22 to 61 m m)
versus 16.5 m m (range, 0 to 46 m m) in the 1-m mol/L
group and 14 m m (range, 5 to 49 m m) in the 3-
m mol/L group. For the control group versus the 1-
m mol/L BQ 788 group, the median difference was
16.0 m m, with 95% confidence intervals that were 7.5
and 28.0 (P = .008). For the control group versus the
3-m mol/L group, the median difference was 16.0 m m,
with 95% confidence intervals that were 9.0 and 30.0
(P = .03; Fig 3). In addition, there was no further sig-
nificant reduction in neointimal thickness in the 3-
m mol/L group as compared with the 1- m mol/L
group. The median difference was 3.0 m m, with 95%
confidence intervals that were –12.5 and 8.5 (P = .52).
The treatment of the vein segments with the
ETA-selective antagonist BQ 123 did not have any
significant effect on the reduction of neointima for-
mation at either 1 m mol/L or 3 m mol/L. The medi-
an neointimal thickness of the control veins was 24
m m (range, 0 to 56 m m) versus 26 m m (range, 10 to
23 m m) in the 1-m mol/L group and 26 m m (range,
5 to 54 m m) in the 3-m mol/L group. The median
difference was 0.0, with 95% confidence intervals
that were –10.0 and 13.5, and –9.5 and 21.0,
respectively. The P value was 1.00 in both compar-
isons (Fig 4). 
DISCUSSION
Although a large number of pharmacologic agents
have been shown to reduce IH in animal models, an
overwhelming majority of the clinical pharmacologic
studies reported to date have failed to show a signifi-
cant reduction in the incidence rate of restenosis in
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humans.38,39 The drugs that have failed in human tri-
als include heparin, hirudin, angiotensin converting
enzyme inhibitors, angiopeptin, calcium channel
blockers, colchicine, and corticosteroids.39 These
results are in sharp contrast with the often promising
results obtained in animal experimental models.40
The study described here uses the precise tissue that
causes the clinical problem—the human saphenous
vein. The main drawback of this in vitro model is that
it does not experience flow conditions, and we previ-
ously have demonstrated that vein segments cultured
under conditions of laminar flow and high shear stress
do not develop IH, whereas vein cultured under low
or no flow conditions does develop a neointima.41 In
vivo, vein grafts have been shown to develop stenosis
at sites of low or turbulent flow and hence low shear
stress, where one would therefore expect to observe a
locally increased production of ET-1.
A growing body of evidence shows that ET-1
plays a major role in the development of IH in
human arteries and veins, and the finding that
bosentan and BQ 788 significantly reduce the devel-
opment of IH in organ-cultured LSV supports this
view and also implies a major role for the ETB recep-
tor subtype in the pathogenesis of neointima forma-
tion. The percentage reduction in neointima that is
achieved with bosentan (70%) and BQ 788 (50%) is
considerably greater than we have found in the same
model with therapeutic levels of either the
angiotensin converting enzyme inhibitor losartan
(30%)42 or with low molecular weight heparin
(0%).43 The concentration of bosentan used (10
m mol/L) in this study is in the middle of the thera-
peutic serum levels achieved after oral administra-
tion.44 The chosen concentrations of BQ 123 also
have been shown to be associated with significant
and selective ETA receptor antagonism.45
The present study as it stands does not identify
whether the effects of the ET receptor antagonists
are on proliferation or on migration. A recent in
vitro study that was performed in this laboratory
showed that bosentan, BQ123, and BQ788 all sig-
nificantly inhibited the proliferative response of the
cultured human saphenous vein smooth muscle cells
to ET-1 [unpublished observations]. Studies that
investigate the effects of these drugs on migration
are currently in progress.
In support of our current observations, previous
studies that used balloon-injured animal arteries also
have proposed a role for the ETB receptor in neoin-
timal formation. It has been shown that chronic
administration of the nonpeptide ETA/ETB recep-
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Fig 1. Representative transverse sections of long saphenous vein cultured for 14 days and
stained with monoclonal anti–smooth muscle actin and Miller’s elastin, which shows neointimal
formation (arrows) at luminal surface. Control veins treated with vehicle only (A) developed a
significantly thicker neointima than bosentan-treated veins (B). (Original magnification · 160.)
FPO
tor antagonist SB 209670 ameliorates the neointima
formation observed in the rat carotid artery.18
Furthermore, in agreement with the present study,
the selective ETA receptor antagonist BQ 123 was
found to be ineffective in this role, an outcome that
implicates the ETB receptor subtype in the genesis of
neointima formation.26 Another study with balloon-
injured rabbit carotid arteries22 showed a markedly
elevated ET-1 immunoreactivity in injured arteries,
together with a doubling of ETB receptor density
that was expressed predominantly in the neointima.
The same study also showed that the chronic intra-
venous administration of BQ 123 at concentrations
that were sufficient to antagonize the ETA receptors
had no effect on neointima formation. These obser-
vations also highlight the increased relative impor-
tance of the ETB receptor subtype in the synthetic
phenotype of smooth muscle cells that comprise the
fibroproliferative stages of IH and restenosis. The
above results and those of the present study suggest
that ET inhibition may have an important part to
play in the amelioration of IH in human saphenous
vein. The results also raise the possibility that selec-
tive ET-1 antagonists could serve as novel therapeu-
tic agents in the control of restenosis.27 Many drug
companies now are developing orally active ET
antagonists with the intention of producing drugs
with a therapeutic potential in man. The preventing
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Fig 2. Scatter plot shows neointimal thicknesses of 14
paired long saphenous vein segments. Vein segments were
cultured for 14 days in the absence or presence of nonselec-
tive endothelin receptor antagonist bosentan (10 m mol/L).
Significance was tested with Wilcoxon signed rank test. 
Fig 4. Scatter plot shows neointimal thicknesses of 10
paired long saphenous vein segments cultured in the
absence or presence of endothelin-A selective antagonist
BQ 123 (3 m mol/L and 1 m mol/L). Significance was test-
ed with Wilcoxon signed rank test.
Fig 3. Scatter plot shows neointimal thicknesses of 10
paired long saphenous vein segments cultured in the
absence or presence of endothelin-B selective antagonist
BQ 788 (3 m mol/L and 1 m mol/L). Significance was test-
ed with Wilcoxon signed rank test.
of the possible pathophysiologic effects of ET at its
receptors with selective antagonists might represent
a major advance in pharmacotherapy. Some of the
agents are receptor specific for the ETA or the ETB
subtype, but others are nonspecific. We are current-
ly investigating the time course of the expression of
ETA and ETB in sequentially cultured vein segments
between day 0 and day 14 with PCR, radioligand
binding, and in-situ hybridization.
The present study examined only 1 time point—
14 days. We previously have shown that neointimal
thickening reaches a maximum between day 10 and
day 14 in culture.31 Recently, we have shown that
ET-1 production with cultured control veins peaks
around day 6, with a rapid “fall off” by day 12
[unpublished results]. Taken together, these obser-
vations suggest that a continuous therapy during the
14 days would probably be necessary to achieve a
durable response.
It has been shown that infusion of ET-1 into the
brachial artery of healthy men causes a venoconstric-
tion that can be abolished by the coinfusion of the
ETA selective antagonist BQ 123.46 The same study
also showed that the infusion of BQ 123 alone
caused a progressive dilatation with a resultant
increase in the forearm blood flow rate of 64%.
These observations suggest that the endogenous
generation of ET-1 contributes to the maintenance
of vascular tone in states of normal and elevated
blood pressure. Chronically elevated ET-1 levels and
the activation of the ETA receptor also have been
shown to play a direct and contributary role in the
progression of chronic heart failure in rabbits.47
Therefore, specific ETA antagonists may have poten-
tial as vasodilators in the treatment of diseases that
are associated with vasoconstriction, such as hyper-
tension and chronic heart failure.
In contrast, the observations that were made in
this study suggest a direct role for the ETB receptor
in the development of IH. Therefore, the specific
antagonism of the ETB receptor may attenuate the
development of human saphenous vein graft steno-
sis, without the undesirable effects of ETA antago-
nism, which might result from the administration of
a nonselective ET receptor antagonist.
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